Latest Headlines

Online Exclusive

Opioid Overdose Tops List of Leading Causes of Death in the...

The odds of dying from an accidental opioid overdose in the U.S. are greater than those of dying in a car accident, according to...

U.S. Veterans to Have Increased Access to Private Care

As part of the Mission Act of 2018, the U.S. Department of Veterans Affairs (VA) is planning to allow veterans to use their health...

Cover Story

Predatory Publishing: The Dark Side of the Open-Access Movement

In October 2016, we dived deep into the open-access (OA) movement – a publishing model in which a scientific article is made freely available – examining the benefits and the drawbacks of this approach to research (“Public Access: The Pros and Cons of Open-Access Publishing”). This month, we take a closer look at another, darker side of scientific publishing: predatory publishing. This segment of the OA publishing movement is characterized by publishers that “unprofessionally exploit” the gold OA model (in which the final version of a manuscript is made freely available on publication), primarily for profit, according to Jeffrey Beall, MSLS, one of the most vigilant watchdogs of predatory publishing, and operator of the website Scholarly Open Access. Sometimes called “vanity presses,” these entities publish practically any materials that come their way, as long as authors are willing to pay a submission and publication fee. Critics – and they are legion...

Clinical News

Latest Videos

Rivaroxaban Prevents Cancer-Associated Venous Thromboembolism

Alok Khorana, MD, shares results from the CASSINI trial, which found that treatment with rivaroxaban reduced the risk of venous thromboembolism in patients receiving...

Ravulizumab: A New Treatment Option for PNH?

Austin Kulasekararaj, MD, MBBS, MRCP, FRCPath, shares results from a phase III study comparing ravulizumab with eculizumab in patients with paroxysmal nocturnal hemoglobinuria.

A Rapid, Inexpensive Screening Test for Sickle Cell Disease in Uganda

Erik Serrao, PhD, discusses the HemoTypeSC test, which provides a rapid, cost-effective screening method for sickle cell disease in newborns living in limited-resource settings.

Elotuzumab Combination Prevents Progression from Smoldering to Symptomatic Myeloma

Irene Ghobrial, MD, shares results from a phase II trial, in which 84 percent of patients with high-risk smoldering multiple myeloma responded to treatment...

On Location

An ASH Annual Meeting Post-Vivum

“So, what did you learn from ASH?” asked my advisor a couple of weeks after...

Transplant or No Transplant for Older, Fit Patients With MDS?

Hematopoietic cell transplantation (HCT) with reduced-intensity conditioning improved overall survival (OS) in older patients with...

Good News on the HORIZON: Melflufen Induces Response in Heavily Refractory Myeloma

One-third of patients with relapsed/refractory multiple myeloma (MM) that was refractory to pomalidomide and/or daratumumab...

ECHELON-2: Brentuximab Vedotin Combination Outperforms CHOP for Peripheral T-Cell Lymphomas

Results from the phase III ECHELON-2 trial showed that brentuximab vedotin added to a combination...

Selinexor Induces Deep Responses in Refractory Multiple Myeloma

More than one-quarter of patients with refractory multiple myeloma (MM) responded to treatment with a...

REACHing Children With Sickle Cell Anemia in Sub-Saharan Africa

Daily treatment with hydroxyurea was feasible, well-tolerated, and safe for children with sickle cell anemia...
Advertisement

Sign Up for our enewsletter!

Subscribe to our newsletter to receive the latest news, updates and online exclusive content.

8,802FollowersFollow
7,062SubscribersSubscribe

Is a Longer Schedule of Decitabine More Effective Than a 5-Day Schedule in Older...

For older patients with treatment-naïve acute myeloid leukemia (AML), research has suggested that a 10-day treatment schedule of the hypomethylating agent decitabine is associated...
WIB_icon

Enasidenib Induces Molecular Remissions in IDH2-Mutated, Relapsed/Refractory AML

A first-in-human trial of patients with relapsed and/or refractory, IDH2-mutated acute myeloid leukemia (AML) found that the IDH2 inhibitor enasidenib was an effective salvage...
WIB_icon

Ravulizumab: A New Complement Inhibitor for Patients With Paroxysmal Nocturnal Hemoglobinuria

Ravulizumab was noninferior to eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) who had never received treatment with complement inhibitors, according to findings from...

FDA Approves Gilteritinib for FLT3-Mutated AML

The oral FLT3/AXL inhibitor gilteritinib was approved by the FDA for the treatment of adult patients with FLT3-mutated, relapsed or refractory AML. The FDA...

First Biosimilar for Rituximab Gains Approval

The FDA approved rituximab-abbs, the first biosimilar of rituximab, for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin lymphoma (NHL). This marks the...